The significance of the senescence pathway in breast cancer progression

Journal of Clinical Pathology

Volumn 66, Issue 6, 2013, Pages 491-495

  Pare, Rahmawati ^a,b   Yang, Tao ^a,b,c   Shin, Joo Shik ^a,b   Lee, Cheok Soon ^a,b,c,d,e,f  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; CATHEPSIN B; CAVEOLIN 1; CYSTEINE RICH PROTEIN 61; PROSAPOSIN; PROTEIN P16; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENESCENCE;

BREAST CANCER; CANCER RESEARCH; CELLULAR SENESCENCE;

AGING; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOLOGICAL MARKERS; BREAST; BREAST NEOPLASMS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 84878320273     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201081     Document Type: Review

References (90)

1. Officioso A, Ferri P, Esposito V, et al. Adopted girls with idiopathic central precocious puberty: observations about character. J Pediatr Endocrinol Metab 2004;17:1385-92. (Pubitemid 39433513)
2. Australian Institute of Health and Welfare & Australian Association of Cancer Registries. Cancer in Australia: an overview, 2010. Canberra: AIHW, 2010.
3. Persichetti P, Di Lella F, Marangi GF, et al. Leiomyosarcoma of the scrotum arising from the dartos muscle: a rare clinicopathological entity. In Vivo 2004;18:553-4. (Pubitemid 39409628)
4. Wilkerson P, Dedes KJ, Lopez-Garcia M, et al. The molecular evolution of breast cancer precursors and risk indicators. In: Kahán Z. Breast cancer, a heterogeneous disease entity: Springer Netherlands, 2011: 89-117.
5. Weinberg RA. Cancer: is a genetic disorder. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB, eds. The Molecular Basis of Cancer. 3rd edn. Philadelphia: Saunders Elsevier, 2008: 3-16.
6. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642-42.
7. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621.
8. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472-6.
9. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 2009;11:59-98.
10. Nuss JE, Choksi KB, DeFord JH, et al. Decreased enzyme activities of chaperones PDI and BiP in aged mouse livers. Biochem Biophys Res Commun 2008;365:355-61. (Pubitemid 350137297)
11. Cho KA, Ryu SJ, Oh YS, et al. Morphological adjustment of senescent cells by modulating caveolin-1 status. J Biol Chem 2004;279:42270-78. (Pubitemid 39313676)
12. Chen QM, Tu VC, Catania J, et al. Involvement of Rb family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis induced by hydrogen peroxide. J Cell Sci 2000;113:4087-97. (Pubitemid 32194533)
13. Hino M, Doihara H, Kobayashi K, et al. Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today 2003;33:486-90. (Pubitemid 36808197)
14. Afshari CA, Vojta PJ, Annab LA, et al. Investigation of the role of G1/S cell cycle mediators in cellular senescence. Exp Cell Res 1993;209:231-37.
15. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192:547-56.
16. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci 1995;92:9363-67.
17. Untergasser G, Koch HB, Menssen A, et al. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002;62:6255-62. (Pubitemid 35244479)
18. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci 1992;89:10114-18.
19. von Zglinicki T, Saretzki G, Ladhoff J, et al. Human cell senescence as a DNA damage response. Mech Ageing Dev 2005;126:111-17. (Pubitemid 40018484)
20. Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 2004;24:473-8. (Pubitemid 39425160)
21. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602. (Pubitemid 27152402)
22. Matarazzo MR, Lembo F, Angrisano T, et al. In vivo analysis of DNA methylation patterns recognized by specific proteins: coupling CHIP and bisulfite analysis. Biotechniques 2004;37:666-8, 70, 72-3.
23. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell 2000;102:407-10.
24. Lin TY, Cheng YC, Yang HC, et al. Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis. Oncogene 2012;31:3287-97.
25. Pelengaris S, Khan M. Introduction. In: Pelengaris S, Khan M. The molecular biology of cancer. UK: Blackwell Publishers, 2007: 1-34.
26. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nature Reviews. Cancer 2003;3:286.
27. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-7. (Pubitemid 44864442)
28. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436:725-30. (Pubitemid 41117277)
29. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005;436:660-5. (Pubitemid 41117262)
30. Mousses S, Ozcelik H, Lee PD, et al. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 1995; 4:1089-92.
31. Korotchkina LG, Leontieva OV, Bukreeva EI, et al. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010;2:344-52.
32. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4. (Pubitemid 41117276)
33. Ha L, Ichikawa T, Anver M, et al. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A 2007;104:10968-73. (Pubitemid 47175210)
34. Dankort D, Filenova E, Collado M, et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-84.
35. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature 2005;436:642. (Pubitemid 41117258)
36. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60. (Pubitemid 46232886)
37. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:e301.
38. da Silva M, Esposito E, Moody JD. Metabolism of aromatic hydrocarbons by the filamentous fungus Cyclothyrium sp. Chemosphere 2004;57:943-52. (Pubitemid 39360326)
39. Cooper WA, Kohonen-Corish MR, Zhuang L, et al. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 2008;113:135-42. (Pubitemid 351976394)
40. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46. (Pubitemid 34606876)
41. Jackson James, Pant GV, et al. p53-Mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012;21:793-806.
42. Jeyapalan JC, Ferreira M, Sedivy JM, et al. Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev 2007;128:36-44. (Pubitemid 46073058)
43. Wang C, Jurk D, Maddick M, et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 2009;8:311-23.
44. Campisi J, Kim SH, Lim CS, et al. Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 2001;36:1619-37. (Pubitemid 32982869)
45. Chang BD, Watanabe K, Broude EV, et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 2000;97:4291-6. (Pubitemid 30226126)
46. Chang B-D, Swift ME, Shen M, et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci 2002;99:389-94. (Pubitemid 34060371)
47. Paradis V, Youssef N, Dargere D, et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001;32:327-32. (Pubitemid 32246808)
48. Bartek J, Iggo R, Gannon J, et al. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
49. Done SJ, Eskandarian S, Bull S, et al. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001;93:700-4. (Pubitemid 32492811)
50. Formisano E, Esposito F, Di Salle F, et al. Cortex-based independent component analysis of fMRI time series. Magn Reson Imaging 2004;22:1493-504. (Pubitemid 40221944)
51. Feige B, Scheffler K, Esposito F, et al. Cortical and subcortical correlates of electroencephalographic alpha rhythm modulation. J Neurophysiol 2005;93:2864-72. (Pubitemid 40575749)
52. Esposito LW, Colwell JE, Larsen K, et al. Ultraviolet imaging spectroscopy shows an active saturnian system. Science 2005;307:1251-5. (Pubitemid 40299964)
53. Del Puente A, Migliaccio S, Esposito A, et al. A reappraisal of therapeutic approaches to osteoporosis. Aging Clin Exp Res 2004;16(Suppl3):42-6.
54. Esposito A, Setola C, Del Puente A. Modifying nutritional risk factors. Aging Clin Exp Res 2004;16(Suppl3):15-19.
55. Milde-Langosch K, Bamberger A-M, Rieck G, et al. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001;67:61-70. (Pubitemid 32703389)
56. Zhang J, Pickering CR, Holst CR, et al. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 2006;66:10325-31. (Pubitemid 44799751)
57. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413:86-91. (Pubitemid 32843493)
58. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59. (Pubitemid 27513656)
59. Esposito A, Gugliucci G, Del Puente A. Epidemiology and nutritional risk factors. Aging Clin Exp Res 2004;16(Suppl3):10-14.
60. Vestey S, Sen C, Calder C, et al. p14ARF expression in invasive breast cancers and ductal carcinoma in situ - relationships to p53 and Hdm2. Breast Cancer Res 2004;6(5):R571-85.
61. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996;2:1591-9. (Pubitemid 126447455)
62. Diaz Flaque MC, Vicario R, Proietti CJ, et al. Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids 2012. http://dx.doi.org/10.1016/j.steroids.2012.11.003.
63. Xu D, Takeshita F, Hino Y, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011;193:409-24.
64. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24. (Pubitemid 46211327)
65. Brown NE, Jeselsohn R, Bihani T, et al. Cyclin d1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res 2012;72:6477-89.
66. Capparelli C, Chiavarina B, Whitaker-Menezes D, et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012;11:3599-610.
67. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001;3:323-7. (Pubitemid 32851163)
68. Colavitti R, Finkel T. Reactive oxygen species as mediators of cellular senescence. IUBMB Life 2005;57:277-81. (Pubitemid 40904255)
69. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005;37:961-76. (Pubitemid 40311739)
70. Salerno M, Lettiero T, Esposito-del Puente A, et al. Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism. Eur J Endocrinol 2004;151:689-94. (Pubitemid 40090007)
71. Krtolica A, Parrinello S, Lockett S, et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001;98:12072-7. (Pubitemid 32959828)
72. Tsai KKC, Chuang EY-Y, Little JB, et al. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res 2005;65:6734-44. (Pubitemid 41060711)
73. Sarkisian CJ, Keister BA, Stairs DB, et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007;9:493-505. (Pubitemid 46696530)
74. Davalos AR, Coppe JP, Campisi J, et al. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010;29:273-83.
75. Bouchet C, Hacene K, Martin PM, et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999;17:3048-57. (Pubitemid 29470632)
76. Sternlicht MD, Lochter A, Sympson CJ, et al. The stromal proteinase MMP3/ stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46. (Pubitemid 29344902)
77. Figueira RC, Gomes LR, Neto JS, et al. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009;9:20.
78. Lin S, Yang J, Elkahloun AG, et al. Attenuation of TGF-beta signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol Biol Cell 2012;23:1569-81.
79. Ernsberger U, Esposito L, Partimo S, et al. Expression of neuronal markers suggests heterogeneity of chick sympathoadrenal cells prior to invasion of the adrenal anlagen. Cell Tissue Res 2005;319:1-13. (Pubitemid 40104634)
80. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269-77. (Pubitemid 39545399)
81. Qian Y, Zhang J, Yan B, et al. DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 2008;283:2896-905.
82. Chakrabarti J, Turley H, Campo L, et al. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer 2004;91:954-58. (Pubitemid 39273790)
83. Li Y, Xie M, Yang J, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006;25:3296-306. (Pubitemid 43846314)
84. Liu X, Yue P, Khuri FR, et al. Decoy Receptor 2 (DcR2) Is a p53 Target Gene and Regulates Chemosensitivity. Cancer Res 2005;65:9169-75. (Pubitemid 41507980)
85. Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004;89:1002-7.
86. Esposito M, Worthington HV, Coulthard P. Interventions for replacing missing teeth: treatment of perimplantitis. Cochrane Database Syst Rev 2004(4):CD004970.
87. Comani S, Mantini D, Lagatta A, et al. Time course reconstruction of fetal cardiac signals from fMCG: independent component analysis versus adaptive maternal beat subtraction. Physiol Meas 2004;25:1305-21. (Pubitemid 39423329)
88. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004;109:786-92. (Pubitemid 38405630)
89. Ganten TM, Sykora J, Koschny R, et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009;87:995-1007.
90. Martinez-Ferrandis JI, Rodríguez-López R, Milne RL, et al. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer biomarkers. IOS Press, 2007;3:89-93.